Drug Profile
Infigratinib - Helsinn/QED Therapeutics
Alternative Names: BBP-831; BGJ-398; BGJ-398 phosphate; Febseltiq; Infigratinib phosphate; NVP-BGJ398; TRUSELTIQLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Array BioPharma; Helsinn; LianBio; Novartis; Novartis Oncology; QED Therapeutics
- Class Aniline compounds; Antineoplastics; Chlorobenzenes; Methylurea compounds; Phenyl ethers; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cholangiocarcinoma
- Phase III Achondroplasia; Bladder cancer; Urogenital cancer
- Phase II Gastric cancer; Head and neck cancer; Oesophageal cancer
- Phase I/II Solid tumours
- Preclinical Hypochondroplasia
- No development reported Breast cancer; Glioma
- Discontinued Glioblastoma; Haematological malignancies; Malignant melanoma